Search results for " thymoma"

showing 5 items of 5 documents

Tobacco smoking and alcohol consumption as risk factors for thymoma - A European case-control study

2019

PURPOSE: Hardly anything is known about the aetiology of thymoma. This paper presents data regarding tobacco smoking and alcohol consumption in relation to thymoma from the first case-control study performed on this rare tumour.METHODS: A European multi-centre case-control study including incident cases aged 35-69 years with thymoma between 1995 and 1997, was conducted in seven countries. A set of controls, used in seven parallel case-control studies by the same research group was used, including population-based controls from five countries and hospital controls with colon cancer from two countries. Altogether 103 cases, accepted by a reference pathologist, 712 colon cancer controls, and 2…

AdultMaleCancer Researchmedicine.medical_specialtyThymomaAlcohol DrinkingThymomaEpidemiologyColorectal cancerThymus cancerPopulationMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAlcohol; Case-control study; Risk factors; Thymoma; Thymus cancer; Tobacco smokingeducation.field_of_studybusiness.industryCase-control studyCase-control studyMiddle Agedmedicine.diseaseTobacco smokingIncreased riskOncologyRisk factorsCase-Control Studies030220 oncology & carcinogenesisEtiologyFemalebusinessAlcoholAlcohol consumption
researchProduct

Thymoma and pure red cell aplasia in a patient with systemic lupus erythematosus.

1995

We present the case of a female patient with a diagnosis of systemic lupus erythematosus (SLE) at the age of 54 years. At the age of 63 years, she suffered from malignant thymoma and 3 years after removal of the thymoma a diagnosis of pure red cell aplasia (PRCA) was established. This is, to our knowledge, the first report of the occurrence of SLE, thymoma and PRCA in the same patient. The case is discussed with regard to the already known associations between these diseases.

Adultmedicine.medical_specialtySystemic diseasePathologyThymomaThymomaImmunologyPure red cell aplasiaBone Marrow Aplasiaurologic and male genital diseasesRed-Cell Aplasia PureRheumatologyimmune system diseasesBone Marrowhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLupus Erythematosus Systemicskin and connective tissue diseasesMalignant ThymomaLupus erythematosusThymus Neoplasmbusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseConnective tissue diseaseDermatologyFemalebusinessScandinavian journal of rheumatology
researchProduct

Minimal manifestation status and prednisone withdrawal in the MGTX trial

2020

ObjectiveTo examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).MethodsThis study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody–positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18–65 years at enr…

Malemedicine.medical_treatmentAzathioprinelaw.invention0302 clinical medicineRandomized controlled trialPrednisonelawMedicineSingle-Blind Method030212 general & internal medicineYoung adultMiddle AgedThymectomyCombined Modality TherapySubstance Withdrawal Syndrome3. Good healthSettore MED/26 - NEUROLOGIA6.1 PharmaceuticalsAnesthesiaadolescent; adult; animals; combined modality therapy; female; humans; immunosuppressive agents; male; middle aged; myasthenia gravis; prednisone; rats; single-blind method; substance withdrawal syndrome; thymoma; thymus neoplasms; young adult; thymectomyCognitive SciencesFemaleImmunosuppressive Agentsmedicine.drugAdultThymomaAdolescentThymomaClinical Trials and Supportive ActivitiesClinical SciencesMGTX study groupAutoimmune DiseaseArticleYoung Adult03 medical and health sciencesRare DiseasesClinical ResearchMyasthenia GravisPost-hoc analysisAnimalsHumansNeurology & Neurosurgerybusiness.industryNeurosciencesEvaluation of treatments and therapeutic interventionsThymus Neoplasmsmedicine.diseaseMyasthenia gravisRatsThymectomyPrednisoneNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

2022

Abstract This overview of the fifth edition of the WHO classification of thymic epithelial tumors (including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]), mediastinal germ cell tumors, and mesenchymal neoplasms aims to (1) list established and new tumor entities and subtypes and (2) focus on diagnostic, molecular, and conceptual advances since publication of the fourth edition in 2015. Diagnostic advances are best exemplified by the immunohistochemical characterization of adenocarcinomas and the recognition of genetic translocations in metaplastic thymomas, rare B2 and B3 thymomas, and hyalinizing clear cell carcinomas. Advancements at the molecular and tumor biolog…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsThymomaThymomaAdenocarcinomaNeuroendocrine tumorsWorld Health OrganizationThymic carcinoma03 medical and health sciences0302 clinical medicineGerm cell tumormedicineHumansGerm cell tumor; NET G3; Thymic carcinoma; Thymic neuroendocrine tumor; Thymoma; WHO classificationThymic carcinoma030304 developmental biologyWHO classification0303 health sciencesbusiness.industryMesenchymal stem cellMediastinumMediastinumThymus Neoplasmsmedicine.disease3. Good healthThymic neuroendocrine tumorGerm Cellsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisGerm cell tumorsNET G3businessClear cellGerm cellJournal of Thoracic Oncology
researchProduct

EBV reactivation in a patient undergoing chemotherapy for invasive thymoma

2007

Over the last few years evidence has emerged to indicate the involvement of herpes viruses in several infectious complications observed in patients undergoing antiblastic chemotherapy. We present a case of bilateral parotiditis due to EBV reactivation in a patient who had received chemotherapy because of an invasive thymoma. In October 2006, a 53-year-old man with pulmonary and pleural metastases owing to an invasive thymoma, was started on chemotherapy with cisplatin, adriamycin and cyclophosphamide. In January 2007, after consultation with an infectious disease specialist, the patient was admitted to the oncology department because of bilateral swelling of the parotid glands which was mos…

Settore MED/17 - Malattie InfettiveEBV reactivation chemotherapy thymoma
researchProduct